Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAESCs Injection for Refractory aGVHD After Allogeneic HCT
NCT06164288Phase 1Completed
- Sponsor
- Shanghai IxCell Biotech Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Mar 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human amniotic epithelial stem cells in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Shanghai IxCell Biotech Co., Ltd. Primary endpoints: Number of Subjects with Dose-Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Feb 2024; status: completed.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06164288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06164288.